Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Cheyne-Stokes Respiration

ClinicalTrials.gov lists 28 trials for Cheyne-Stokes Respiration or a narrower condition beneath it. ResMed has the most among industry and government lead sponsors, with 5.

MeSH D002639 Respiratory Tract Diseases C08 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2 Phase 2 Phase 2 2 Phase 3 Phase 3 1 Phase 4 Phase 4 2 Not applicable Not applicable 14 Observational Observational 7 Phase 1 Phase 1 2 Phase 2 Phase 2 2 Phase 3 Phase 3 1 Phase 4 Phase 4 2 Not applicable Not applicable 14 Observational Observational 7

Trials per phase

28 of the 28 trials are tagged with Cheyne-Stokes Respiration itself; the rest are tagged with a narrower condition beneath it.

Get the Cheyne-Stokes Respiration report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Cheyne-Stokes Respiration trials start? (15)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 5

2001: 1 trials (Observational 1) 2005: 1 trials (Not applicable 1) 2007: 4 trials (Observational 1, Not applicable 2, Phase 1 1) 2008: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 2009: 1 trials (Observational 1) 2010: 5 trials (Not applicable 3, Phase 2 1, Phase 1 1) 2011: 1 trials (Observational 1) 2012: 1 trials (Phase 4 1) 2013: 1 trials (Not applicable 1) 2015: 2 trials (Observational 1, Not applicable 1) 2016: 2 trials (Not applicable 1, Phase 3 1) 2017: 1 trials (Not applicable 1) 2018: 2 trials (Observational 1, Not applicable 1) 2023: 1 trials (Not applicable 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 1
2023 1
2018 2
2017 1
2016 2
2015 2
2013 1
2012 1
2011 1
2010 5

No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.

Recruitment duration, a model prediction: none of the 28 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Cheyne-Stokes Respiration trials in? (6)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2
Phase 2 2
Phase 3 1
Phase 4 2
Not applicable 14
Observational 7

How many Cheyne-Stokes Respiration trials are recruiting? (5)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1
Active, not recruiting 1
Completed 20
Terminated 4
Unknown status 2

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Cheyne-Stokes Respiration trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
ResMed 5
Philips Respironics 3
Respicardia, Inc. 2
Asten Sante 1
LudwLudwig Boltzmann Institute for COPD and Respiratory Epidemiology 1

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
No Interventions 1
baclofen 2% 1
Optimized Medical Treatment 1
PO Morphine 1
AVE0657 1

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Cheyne-Stokes Respiration trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
ACUTE CONGESTIVE HEART FAILURE 14 1
LEAD DISLODGEMENT 11 1
VENTRICULAR ARRHYTHMIA 6 1
ACUTE CORONARY SYNDROME 3 1
ATRIAL ARRHYTHMIA 2 1

Which publications cover Cheyne-Stokes Respiration? (39)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Central Sleep Apnea in Patients with Congestive Heart Failure. Sleep medicine clinics 2017 Yes
Distinct Patterns of Hyperpnea During Cheyne-Stokes Respiration: Implication for Cardiac Function in Patients With Heart Failure. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine 2017 Yes
Current and future developments in the field of central sleep apnoea. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2016 Yes
Mechanisms underlying increased mortality risk in patients with heart failure and reduced ejection fraction randomly assigned to adaptive servoventilation in the SERVE-HF study: results of a secondary multistate modelling analysis. The Lancet. Respiratory medicine 2016 Yes
Improvements of central respiratory events, Cheyne-Stokes respiration and oxygenation in patients hospitalized for acute decompensated heart failure. Sleep medicine 2016 Yes

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages